{"id":"https://openalex.org/W2963614034","doi":"https://doi.org/10.1007/s40261-019-00826-0","title":"Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features","display_name":"Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features","alternate_titles":[],"publication_year":2019,"publication_date":"2019-07-18","ids":{"openalex":"https://openalex.org/W2963614034","doi":"https://doi.org/10.1007/s40261-019-00826-0","mag":"2963614034","pmid":"https://pubmed.ncbi.nlm.nih.gov/31317516","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6746674"},"language":"en","primary_location":{"id":"doi:10.1007/s40261-019-00826-0","doi":"https://doi.org/10.1007/s40261-019-00826-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-019-00826-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00826-0.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2963614034"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00826-0.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037083528","display_name":"Katherine Ann Lyseng-Williamson","orcid":"https://orcid.org/0000-0002-5104-1158","observed_orcids":["https://orcid.org/0000-0002-5104-1158"]},"institutions":[{"id":"https://openalex.org/I4210115663","display_name":"Springer Nature (New Zealand)","ror":"https://ror.org/029zamy29","country_code":"NZ","type":"company","lineage":["https://openalex.org/I1313014049","https://openalex.org/I4210112888","https://openalex.org/I4210115663"]}],"countries":["NZ"],"is_corresponding":true,"raw_author_name":"Katherine A. Lyseng-Williamson","raw_affiliation_strings":["Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. DEcorrespondence@springer.com","Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand"],"raw_orcid":"https://orcid.org/0000-0002-5104-1158","affiliations":[{"raw_affiliation_string":"Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. DEcorrespondence@springer.com","institution_ids":["https://openalex.org/I4210115663"]},{"raw_affiliation_string":"Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand","institution_ids":["https://openalex.org/I4210115663"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5037083528"],"corresponding_institution_ids":["https://openalex.org/I4210115663"],"apc_list":{"value":3140,"currency":"USD","value_usd":3140},"apc_paid":{"value":3140,"currency":"USD","value_usd":3140},"fwci":1.3703,"has_fulltext":true,"cited_by_count":99,"citation_normalized_percentile":{"value":0.8049505,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"39","issue":"8","first_page":"805","last_page":"819"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9850000143051147},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9879999756813049},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9700000286102295},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":0.9950000047683716},{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":1.0},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9559999704360962},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.7789999842643738},{"id":"https://openalex.org/keywords/glucagon-suppression","display_name":"glucagon suppression","score":0.9570000171661377},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.972000002861023},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7480000257492065},{"id":"https://openalex.org/keywords/cardiovascular-outcomes","display_name":"cardiovascular outcomes","score":0.8709999918937683},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.828000009059906},{"id":"https://openalex.org/keywords/hypoglycemia-risk","display_name":"hypoglycemia risk","score":0.8920000195503235},{"id":"https://openalex.org/keywords/personalized-treatment","display_name":"personalized treatment","score":0.4749999940395355}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9468036890029907},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.9075106382369995},{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.8481758236885071},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.8288342356681824},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7989614605903625},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.7429830431938171},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7392606735229492},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.5844858884811401},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5048704743385315},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.4872256815433502},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4492274522781372},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.44126689434051514},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.42369043827056885},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38087746500968933},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.37138599157333374},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.3526642918586731},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3371082842350006},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.29072871804237366}],"mesh":[{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40261-019-00826-0","doi":"https://doi.org/10.1007/s40261-019-00826-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-019-00826-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00826-0.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},{"id":"pmid:31317516","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31317516","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical drug investigation","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6746674","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6746674/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Drug Investig","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s40261-019-00826-0","doi":"https://doi.org/10.1007/s40261-019-00826-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-019-00826-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00826-0.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2963614034.pdf","grobid_xml":"https://content.openalex.org/works/W2963614034.grobid-xml"},"referenced_works_count":65,"referenced_works":["https://openalex.org/W169333368","https://openalex.org/W917052595","https://openalex.org/W1536955134","https://openalex.org/W1910083626","https://openalex.org/W1970905724","https://openalex.org/W1976838333","https://openalex.org/W2006573193","https://openalex.org/W2007330805","https://openalex.org/W2022207575","https://openalex.org/W2030228579","https://openalex.org/W2052771129","https://openalex.org/W2054981500","https://openalex.org/W2055754603","https://openalex.org/W2065319712","https://openalex.org/W2072750268","https://openalex.org/W2091480327","https://openalex.org/W2104252114","https://openalex.org/W2140367917","https://openalex.org/W2152984355","https://openalex.org/W2196942236","https://openalex.org/W2207970920","https://openalex.org/W2276028032","https://openalex.org/W2282578582","https://openalex.org/W2321173821","https://openalex.org/W2425644022","https://openalex.org/W2462710388","https://openalex.org/W2463562243","https://openalex.org/W2519510391","https://openalex.org/W2563047690","https://openalex.org/W2578084918","https://openalex.org/W2586129535","https://openalex.org/W2602700371","https://openalex.org/W2604469807","https://openalex.org/W2617257626","https://openalex.org/W2619082960","https://openalex.org/W2738648627","https://openalex.org/W2742669393","https://openalex.org/W2751938332","https://openalex.org/W2754041380","https://openalex.org/W2757494156","https://openalex.org/W2773969925","https://openalex.org/W2774157762","https://openalex.org/W2785139619","https://openalex.org/W2787255324","https://openalex.org/W2789732774","https://openalex.org/W2801613992","https://openalex.org/W2801715295","https://openalex.org/W2808414723","https://openalex.org/W2884698262","https://openalex.org/W2887036440","https://openalex.org/W2889062210","https://openalex.org/W2889221007","https://openalex.org/W2889521172","https://openalex.org/W2889552513","https://openalex.org/W2893883775","https://openalex.org/W2894188801","https://openalex.org/W2902989158","https://openalex.org/W2905322153","https://openalex.org/W2918235691","https://openalex.org/W2948027184","https://openalex.org/W2948612418","https://openalex.org/W3006519701","https://openalex.org/W3026368894","https://openalex.org/W4212810717","https://openalex.org/W4230892627"],"related_works":["https://openalex.org/W1753769072","https://openalex.org/W2123041020","https://openalex.org/W2738794532","https://openalex.org/W2604623769","https://openalex.org/W6902240138","https://openalex.org/W1995257796","https://openalex.org/W2067104263","https://openalex.org/W3211003663","https://openalex.org/W3171499734","https://openalex.org/W2519670213"],"abstract_inverted_index":{"Glucagon-like":[0],"peptide-1":[1],"receptor":[2],"analogues/agonists":[3],"(GLP-1RAs)":[4],"are":[5,115,132],"well":[6,117],"established":[7],"as":[8,22],"effective":[9],"adjuncts":[10],"to":[11,91,101,148],"lifestyle":[12],"modification":[13],"in":[14,25,53,80],"the":[15,54,108,125,150,157],"treatment":[16],"of":[17,110,140,156],"type":[18],"2":[19],"diabetes":[20],"(T2D)":[21],"monotherapy":[23],"or":[24,103],"combination":[26],"with":[27,119,134,143],"oral":[28],"glucose-lowering":[29],"drugs":[30],"\u00b1":[31],"insulin.":[32],"The":[33],"six":[34],"subcutaneous":[35],"GLP-1RA":[36],"formulations":[37],"(i.e.":[38],"twice-daily":[39],"exenatide,":[40],"once-daily":[41],"liraglutide":[42],"and":[43,45,49,56,66,76,87,94,121,131,153],"lixisenatide,":[44],"once-weekly":[46],"dulaglutide,":[47],"exenatide":[48],"semaglutide)":[50],"currently":[51],"available":[52],"EU":[55],"USA":[57],"have":[58,98],"many":[59],"similarities,":[60],"but":[61],"also":[62,97],"some":[63],"unique":[64],"features":[65],"properties.":[67],"By":[68],"stimulating":[69],"GLP-1":[70],"receptors,":[71],"GLP-1RAs":[72,114,144],"increase":[73],"insulin":[74],"secretion":[75],"suppress":[77],"glucagon":[78],"release":[79],"a":[81,135],"glucose-dependent":[82],"manner,":[83],"thereby":[84],"improving":[85],"clinical":[86,151],"patient-reported":[88],"outcomes":[89],"related":[90],"glycaemic":[92],"control":[93],"weight.":[95],"They":[96],"been":[99],"shown":[100],"reduce,":[102],"at":[104],"least":[105],"not":[106],"increase,":[107],"risk":[109,139],"major":[111],"cardiovascular":[112],"outcomes.":[113],"generally":[116],"tolerated,":[118],"gastrointestinal":[120],"injection-site":[122],"reactions":[123],"being":[124],"most":[126],"troublesome":[127],"drug-related":[128],"adverse":[129],"events,":[130],"associated":[133],"very":[136],"low":[137],"intrinsic":[138],"hypoglycaemia.":[141],"Treatment":[142],"should":[145],"be":[146],"customized":[147],"meet":[149],"needs":[152],"personal":[154],"preferences":[155],"individual.":[158]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2963614034","counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":20},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":14},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2019-07-30T00:00:00"}
